Tolerability of indacaterol, a novel once-daily β2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study

Indacaterol had a good overall safety profile and was well tolerated at both doses, with predose FEV1 results on days 14 and 28 indicating 24-hour bronchodilator efficacy.